Karabayas, M., Dospinescu, P., Fluck, N., Kidder, D., Fordyce, G., Hollick, R.J., De Bari, C. and Basu, N. (2020) Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Rheumatology Advances in Practice, 4(2), rkaa069. (doi: 10.1093/rap/rkaa069) (PMID:33381680) (PMCID:PMC7756006)
Text
224000.pdf - Published Version Available under License Creative Commons Attribution. 108kB |
Abstract
Objectives: GCA patients with large vessel involvement (LV-GCA) experience greater steroid requirements and higher relapse rates, compared to classical cranial GCA. Despite the distinct disease course, interventions in LV-GCA have yet to be specifically investigated. This study aimed to evaluate the steroid sparing effect and tolerability of first-line mycophenolate in LV-GCA. Methods: A retrospective cohort study was conducted in patients with LV-GCA identified from a regional clinical database between 2005 and 2019. All cases were prescribed mycophenolate derivatives (mycophenolate mofetil or mycophenolic acid, MYC) at diagnosis and were followed up for at least 2 years. The primary outcome was cumulative steroid dose at 1 year. Secondary outcomes included MYC tolerance, relapse rates and CRP levels at 1 and 2 years. Results: A total of 37 patients (65% female; mean age 69.4, SD7.9) were identified. All cases demonstrated large vessel involvement via CT/PET n=34, CTA n=5 or MRA n=2. After 2 years, 31 patients remained on MYC, whilst 6 switched to methotrexate or tocilizumab due to significant disease relapse. The mean cumulative prednisolone dose at 1 year was 4960 (±1621) mg. Relapse rates at 1 and 2 years were 16.2% and 27% respectively, whilst CRP levels at 1 and 2 years were 4 mg/L (IQR 4-6 mg/L) and 4 mg/L (IQR 4-4 mg/L) respectively. Conclusion: To our knowledge, this is the first effort to assess the effectiveness of any specific agent in LV-GCA. MYC may be both effective in reducing steroid exposure and well tolerated in this sub-population. A future randomised controlled trial is warranted.
Item Type: | Articles |
---|---|
Additional Information: | We are grateful to Versus Arthritis (grant 22088) and PMR/GCA for supporting our work. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Basu, Professor Neil |
Authors: | Karabayas, M., Dospinescu, P., Fluck, N., Kidder, D., Fordyce, G., Hollick, R.J., De Bari, C., and Basu, N. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Research Centre: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology |
Journal Name: | Rheumatology Advances in Practice |
Publisher: | Oxford University Press |
ISSN: | 2514-1775 |
ISSN (Online): | 2514-1775 |
First Published: | First published in Rheumatology Advances in Practice 4(2):rkaa069 |
Publisher Policy: | Reproduced under a Creative Commons license |
University Staff: Request a correction | Enlighten Editors: Update this record